Related Experiment Videos
Rivastigmine in vascular dementia
Rita Moretti1, Paola Torre, Rodolfo M Antonello
1Università degli Studi di Trieste, Istituto di Clinica Neurologica, Ospedale di Cattinara, 34149 Trieste, Italy. moretti@univ.trieste.it
Expert Opinion on Pharmacotherapy
|May 28, 2004
Summary
Rivastigmine, a dual inhibitor of acetylcholinesterase and butyrylcholinesterase, shows promise for treating vascular dementia (VaD). Long-term treatment appears safe and effective for subcortical VaD symptoms.
Area of Science:
- Neuroscience
- Pharmacology
- Geriatrics
Background:
- Vascular dementia (VaD) is associated with cholinergic deficits.
- Subcortical VaD presents with executive dysfunction and behavioral issues due to frontal lobe deterioration.
- Limited studies suggest potential benefits of rivastigmine in VaD.
Purpose of the Study:
- To evaluate the effects of rivastigmine on symptoms of subcortical VaD.
- To assess the safety and efficacy of long-term rivastigmine treatment in VaD patients.
Main Methods:
- Review of limited open-label controlled studies of rivastigmine in VaD.
- Analysis of rivastigmine's impact on characteristic subcortical VaD symptoms.
Main Results:
- Long-term rivastigmine treatment demonstrated safety and effectiveness.
- Observed improvements in cognitive and behavioral domains typical of subcortical VaD.
- Rivastigmine may offer targeted treatment for affected brain areas in VaD.
Conclusions:
- Rivastigmine shows potential as a targeted therapy for subcortical VaD.
- Further large-scale, double-blind studies are necessary to confirm these findings.
- Rivastigmine is a safe and effective option for managing VaD symptoms.